This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Amersdorfer, P. Articles by Marks, J. D. Search for Related Content PubMed PubMed Citation Articles by Amersdorfer, P. Articles by Marks, J. D.

 Previous Article  |  Next Article 

Infect. Immun., Sep 1997, 3743-3752, Vol 65, No. 9
Copyright © 1997, American Society for Microbiology

Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries

P Amersdorfer, C Wong, S Chen, T Smith, S Deshpande, R Sheridan, R Finnern and JD Marks
Department of Anesthesia and Pharmaceutical Chemistry, University of California, San Francisco, 94110, USA.

To produce antibodies capable of neutralizing botulinum neurotoxin type A (BoNT/A), the murine humoral immune response to BoNT/A binding domain (H(C)) was characterized at the molecular level by using phage antibody libraries. Mice were immunized with BoNT/A H(C), the spleens were harvested, and single-chain Fv (scFv) phage antibody libraries were constructed from the immunoglobulin heavy and light chain variable region genes. Phage expressing BoNT/A binding scFv were isolated by selection on immobilized BoNT/A and BoNT/A H(C). Twenty-eight unique BoNT/A H(C) binding scFv were identified by enzyme-linked immunosorbent assay and DNA sequencing. Epitope mapping using surface plasmon resonance in a BIAcore revealed that the 28 scFv bound to only 4 nonoverlapping epitopes with equilibrium constants (Kd) ranging from 7.3 x 10(-8) to 1.1 x 10(-9) M. In a mouse hemidiaphragm assay, scFv binding epitopes 1 and 2 significantly prolonged the time to neuroparalysis, 1.5- and 2.7-fold, respectively, compared to toxin control. scFv binding to epitopes 3 and 4 showed no protection against neuroparalysis. A combination of scFv binding epitopes 1 and 2 had an additive effect on time to neuroparalysis, which increased to 3.9-fold compared to the control. The results suggest that there are two "productive" receptor binding sites on H(C) which lead to toxin internalization and toxicity. Blockade of these two epitopes with monoclonal antibodies may provide effective immunoprophylaxis or therapy against BoNT/A intoxication.

This article has been cited by other articles:

• Mechaly, A., Zahavy, E., Fisher, M. (2008). Development and Implementation of a Single-Chain Fv Antibody for Specific Detection of Bacillus anthracis Spores. Appl. Environ. Microbiol. 74: 818-822 [Abstract] [Full Text]  
• Smith, T. J., Lou, J., Geren, I. N., Forsyth, C. M., Tsai, R., LaPorte, S. L., Tepp, W. H., Bradshaw, M., Johnson, E. A., Smith, L. A., Marks, J. D. (2005). Sequence Variation within Botulinum Neurotoxin Serotypes Impacts Antibody Binding and Neutralization. Infect. Immun. 73: 5450-5457 [Abstract] [Full Text]  
• Cheng, X., Zhang, Y., Kotani, N., Watanabe, T., Lee, S., Wang, X., Kawashima, I., Tai, T., Taniguchi, N., Honke, K. (2005). Production of a Recombinant Single-Chain Variable-Fragment (scFv) Antibody against Sulfoglycolipid. J Biochem 137: 415-421 [Abstract] [Full Text]  
• Nowakowski, A., Wang, C., Powers, D. B., Amersdorfer, P., Smith, T. J., Montgomery, V. A., Sheridan, R., Blake, R., Smith, L. A., Marks, J. D. (2002). Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 99: 11346-11350 [Abstract] [Full Text]  
• Mullaney, B. P., Pallavicini, M. G., Marks, J. D. (2001). Epitope Mapping of Neutralizing Botulinum Neurotoxin A Antibodies by Phage Display. Infect. Immun. 69: 6511-6514 [Abstract] [Full Text]  
• Pless, D. D., Torres, E. R., Reinke, E. K., Bavari, S. (2001). High-Affinity, Protective Antibodies to the Binding Domain of Botulinum Neurotoxin Type A. Infect. Immun. 69: 570-574 [Abstract] [Full Text]